NATHALIA DA SILVA HALLEY NEVES
Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais
P ICR, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
conferenceObject MEG3 and MEG8 aberrant methylation associated with worst prognosis in an infant with neuroblastoma(2020) NOVAK, Estela M.; GIMENEZ, Thamiris Magalhaes; NEVES, Nathalia Halley; VINCE, Carolina Sgarioni Camargo; KREPISCHI, Ana Cristina Victorino; LAPA, Rainer Marco Lopez; CRISTOFANI, Lilian M.; BENDIT, Israel; ODONE FILHO, VicenteconferenceObject LONG TERM COMPLICATIONS IN CHILDREN TREATED FOR ADVANCED NEUROBLASTOMA(2012) HALLEY, Nathalia; CRISTOFANI, Lilian Maria; ALMEIDA, Maria Teresa Assis; MALUF-JUNIOR, Paulo Taufi; CORNACCHIONI, Ana Lucia Beltrati; TEIXEIRA, Roberto Augusto Plaza; ZAMPERLINI-NETO, Gabriele; GOMES, Alessandra Araujo; ODONE-FILHO, VicentePurpose: Advanced neuroblastoma (stage 3 and 4) requires aggressive treatment, including surgery, chemo and radiotherapy and autologous bone marrow transplantation. Although long term survival rates are disappointing, those children who survive are prone to develop long term complications. Our aim is to report the long term complications rate and quality in children treated for stage 3 and 4 neuroblastoma. Methods: The charts of stage 3 and 4 children with neuroblastoma treated from January/1983 through October/2003 were reviewed and those surviving and with no evidence of disease for more than 5 years were selected. Late effects were classified as second malignancies, endocrinological, neuromotor, hepatic, sensorial, benign tumors, infectious diseases and psychiatric disease and others. Associations with treatment modalities were disclosed. Results: Among 263 children with stage 3 and 4 neuroblastoma, 40 (15%) are long term survivors. 20/40 (50%) present one or more complications, being 2 (10%) second malignant neoplasia, 4 (20%) endocrinological disturbances, 4 (20%) neuromotor, 5 (25%) hepatic, 4 (20%) sensorial, 3 (1.1%) benign tumors, and infertility, psychiatric disease and hepatitis C infection in 1 (5%) episode each. 10/20 (50%) of the children were less than 18 months at diagnosis, and 12/20 (60%) were stage 3 and 8/20 (40%) were stage 4. All children were submitted to chemotherapy and 7/20 (35%) to autologous bone marrow transplantation. In 10/20 (50%) patients radiotherapy was also included, and 4/10 (40%) presented functional lesions in the irradiated field. All endocrinologic sequelae were detected in the ABMT group. Second malignant neoplasia were not related to RDT(1 ALL and 1 thyroid carcinoma). Conclusion: Children surviving aggressive therapy for neuroblastoma are at risk of late effects, particularly endocrinological and neurological complications, requiring close observation to prompt intervention when necessary, avoiding impairments in quality of life or even life threatening situations. Second malignant neoplasia require special concern.conferenceObject Identification Somatic Variants FOXO3A and FOXK2 in Neuroblastoma Patients that May Affect Doxorubicin and Platin Chemoterapy(2018) ODONE-FILHO, V.; NEVES, N. H.; GIMENEZ, T. M.; SANTOS, A. R.; VINCE, C. C.; MARCHI, F. A.; KREPISCHI, A. C.; LAPA, R. M.; ZAMPERLINI, G.; CRISTOFANI, L. M.; NOVAK, E. M.conferenceObject CD8 Positive T Cell Number as Indicator of Prognosis in Children with Relapsed or Primarily Refractory Cancer(2018) ODONE-FILHO, V.; CRISTOFANI, L. M.; TEIXEIRA, R. A.; GIMENEZ, T. M.; SANTOS, A. R.; MARCHI, F. A.; LAPA, R. L.; KREPISCHI, A. C.; NOVAK, L. M.; BRUMATTI, M.; PEREIRA, P. L.; AZAMBUJA, A. M.; DORIA-FILHO, U.; CORNACHIONNI, A. L.; VINCE, C. S.; NEVES, N. H.conferenceObject Blinatumomab (BLINA) as Sole Therapy for Relapsed Acute Leukemia (ALL) after Allogenic Hematopoietic Stem Cell Transplantation (HSCT)(2020) PEREIRA, P.; VINCE, C.; BRUMATTI, M.; HALLEY, N.; AZAMBUJA, A.; FERNANDES, J.; HAMERSCHLAK, N.; ZAMPERLINI-NETTO, G.; PEREIRA, A.; KROHLING, D.; ODONE-FILHO, V.conferenceObject Hydroxyurea (HU) Therapy for Patients With Post-Transplant Lymphoproliferative Disease (PTLD): Treatment and Prevention of New Episodes(2020) PEREIRA, P.; VINCE, C.; AZAMBUJA, A.; BRUMATTI, M.; CRISTOFANI, L.; HALLEY, N.; PEREIRA, A.; ZAMPERLINI-NETTO, G.; GUEDES, G.; ODONE-FILHO, V.conferenceObject BLM, AHCY and A Novel PKMYT1 Gene Mutations Identified in Children with Neuroblastoma(2016) NOVAK, E. M.; HALLEY, N.; SANTOS, A. Rangel; GIMENEZ, T. M.; AZAMBUJA, A. M.; VINCE, C. S.; LEE, M. L.; BRUMATTI, M.; PEREIRA, P. L.; BENDIT, I.; CRISTOFANI, L. M.; ODONE-FILHO, V.